We present a pharmacogenetic study of acute antipsychotic (AP)-induced extrapyramidal symptoms (EPS) using an extensive linkage disequilibrium mapping approach in seven-candidate genes with a well-established link to dopamine (DRD2, DRD3, ACE, COMT, DAT, MAO-A, MAO-B). From a cohort of 321 psychiatric inpatients, 81 cases presenting with EPS (Simpson-Angus 43) and 189 controls presenting without EPS (Simpson-Angus p3) took part. Eighty-four-tag single nucleotide polymorphisms (SNPs) in candidate genes were genotyped. After extensive data cleaning, 70 SNPs were analyzed for association of single markers and haplotypes. AP dosage, AP-DRD2 blockade potency and age were identified as susceptibility factors for APinduced EPS. One SNP of the DRD3 gene, rs167771, achieved significant association with EPS risk after Bonferroni correction (nominal P-value 1.3 Â 10
Introduction
Antipsychotic (AP) treatment-emergent extrapyramidal symptoms (EPS) are frequent and serious acute adverse reactions to AP drugs. Even though the exact mechanism underlying EPS is not clear, striatal dopamine D2 receptor (DRD2) blockade is believed to be the principal cause. 1 Several studies have tried to identify potential risk factors for developing EPS, such as younger age, 2 male gender 3 and psychiatric diagnosis, especially mood disorders. 4 Other predictors of EPS are the AP dosage and the AP potency of the DRD2 blockade. 5, 6 More recently, genetic factors have also been considered, including the possible relationship between AP-induced acute EPS and the CYP2D6 genotype. [7] [8] [9] [10] [11] However, the CYP2D6 genotype alone fails to identify all probable cases and other explanations for the occurrence of EPS including genetic variability in AP targets and related molecular structures (Table 1) . Earlier findings by our group showed that genetic variability affecting dopamine availability, such as that in enzymes involved in neurotransmitter metabolism (Cathecol-O-Methyltransferase, COMT), could be more important for AP-induced EPS than genetic variability in AP targets, such as DRD2 and dopamine D3 receptor (DRD3). 12 These results led us to hypothesize that those genes involved in the metabolism and transport of AP and dopamine are good candidate genes for predicting APinduced EPS. Several enzymes participate in the metabolism and transport of dopamine, regulating their availability in the synaptic cleft, such as monoamine oxidase (MAO-A and MAO-B), angiotensin-converting enzyme (ACE) and dopamine transporter (DAT). However, studies focusing on a limited set of single nucleotide polymorphisms (SNPs), based on the functional or suspected functional properties of these SNPs, have failed to show association. 13 A new strategy has emerged from our understanding of linkage disequilibrium (LD) relationships and of how the genome is structured. The human genome is structured in haplotype blocks of low diversity and high LD, allowing the selection of a subset of SNPs that capture most genetic variability in each block.
14 These SNPs are known as the haplotype-tag SNPs (htSNPs). The htSNPs can be used to detect associations without directly genotyping the true susceptibility variant. The International HapMap Project has cataloged a large number of common htSNPs that are useful for designing association studies. The corresponding data can be accurately tested with the continuous improvement of high-throughput genotyping technologies. 15 Here, we expand our earlier studies by using an extensive LD mapping approach with htSNPs selected from HapMap data from these dopaminergic genes (ACE, COMT, DAT, DRD2, DRD3, MAO-A, MAO-B). This strategy allowed the analysis of the most common variants in the defined candidate regions with the aim of finding additional markers that indicate higher risk of AP-induced EPS than that reported for the classic markers.
Results
The psychiatric diagnosis of cases (patients treated with APs who presented with EPS) showed that 69% of the patients had schizophrenia or related disorders and 30% had bipolar disorder. In the control group (patients treated with APs without EPS), 87.9% were diagnosed with schizophrenia and 12% with bipolar disorder. The cases and the controls had similar distribution in terms of gender and smoking patterns or substance abuse. Age was significantly different between cases (32.6±13) and controls (37.6±16) in the overall group (P ¼ 0.01). This difference compelled us to adjust the multivariate analysis for this factor. Different EPS were reported in the case group, with bradykinesia being the most prevalent form (54%), followed by dystonia (24%), rigidity (18%), tremor (2%) and dyskinesia (2%). Table 2 shows the AP drugs administered in both groups and the mean and standard deviations of the AP dosage calculated as chlorpromazine-equivalent daily dose (CEDD) and categorized in three subgroups (low, medium and high). Table 3 shows a multivariate analysis of age, AP dosage and AP-EPS potency and reveals an association between these variables and risk of EPS. On the basis of the results, we decided to adjust the multivariate analysis for these factors.
The results of the association analysis for single SNPs are shown in Figure 1 . When the overall group was analyzed, none of these SNPs achieved Po0.012, the nominal P-value expected by chance ( Figure 1a ). When our sample was stratified by AP, and the analysis was restricted to those patients treated with risperidone, Po0.05 values were observed in 7.1% of the tests (4.3% expected by chance), and Po0.012 values were observed in 5.7% of tests (1.4% expected by chance) (Figure 1b) . Only one SNP of the DRD3 gene, rs167771, achieved significant P-values after Bonferroni correction (nominal P-value 1.3 Â 10 À4 , statistical power 97.6%) ( Table 4) .
The various haplotypes inferred from the genes studied, including DRD3, showed no significant differences in their susceptibility to AP-induced EPS (data not shown).
Discussion
The aim of this study was to evaluate the possible association between the genetic polymorphisms in candidate genes with a well-established link to dopamine (ACE, COMT, DAT, DRD2, DRD3, MAO-A, MAO-B) and the risk of acute AP-induced EPS (acute dystonia, parkinsonism, akathisia), of which approximately 50% occur within 2 days of AP treatment and 90% occur within 5 days of treatment. 16 Although the situation is better than it was during the preclozapine era, the EPS problem has not gone away. This is seen in larger effectiveness trials, such as comparative effectiveness of antipsychotic medications in patients with schizophrenia, in which 10.5% of patients stopped their assigned medication for EPS-related reasons. 17 Pharmacogenetics studies in psychopharmacology entail complex trials because of the multiplicity of diagnoses, treatments and dosage used, and to the large number of confounding factors (duration of treatment, concomitant medication, earlier medication and compliance). Therefore, the recruitment of homogenous participants for these studies is a complex process. Our study was a prospective cohort study, in which the patients were recruited on admission to our Hospital, designed in a real-life setting. The heterogeneity of EPS and inclusion of different drugs and dosages might be a weakness. In this situation, dose Effects of DRD3 polymorphisms in risperidone-induced EPS P Gassó et al equivalence estimations are applied in the statistical analysis to homogenize the data. Furthermore, we categorized the CEDD values into three groups (high, medium and low dosage), as described earlier. 18 These strategies are commonplace in psychopharmacology and have been used in several pharmacogenetic studies. 19, 20 This pharmacogenetic study revealed an association of risperidone-induced EPS with rs167771, a common genetic variant in the third intron of the DRD3 gene. The D3 receptor was cloned and characterized as a D2-like receptor in 1990. 21 Pharmacological studies have shown that many AP drugs also show close affinity with the D3 receptor. Thus, this protein may be an important target for AP drugs. 22 Risperidone, an atypical AP, is widely used as a first-line drug for schizophrenia treatment. In fact, it was the most prescribed drug in our group (48 cases and 84 controls). Considering sample size, no stratification was available for other drugs. Higher antagonistic activity of risperidone at a 5-HT 2A receptor than at D2 receptor is assumed to contribute a lot to its atypical property, but may not be sufficient in itself. 23 Single photon emission tomography with [ 123 I]epidelpride showed that risperidone also had close affinity with D3 receptors. 24 However, the contributions of D3 receptor antagonism to the AP activity of risperidone are still to be examined.
Among the SNPs identified in the DRD3 gene, Ser9Gly polymorphism (rs6280) has been the most extensively investigated. Recently, several studies have suggested an association between the D3 receptor Ser9Gly polymorphism and AP response to risperidone, but the results were Table 3 The age, AP dosage and AP-EPS potency-dependent risk for EPS Three case and three controls missing due to lack of AP information.
Effects of DRD3 polymorphisms in risperidone-induced EPS P Gassó et al inconsistent. [25] [26] [27] [28] A series of reports including a recent metaanalysis have suggested an association in favor of the Gly9 vs the Ser9 variant with an increased risk of developing APinduced tardive dyskinesia. [29] [30] [31] However, in our sample, no association with EPS was observed for this polymorphism, which is consistent with the earlier reports in the literature. 32, 33 Interestingly, the same common variant in DRD3 associated with AP-induced EPS in our study, rs167771, was associated with autism spectrum disorder (ASD) in a two-stage design association study analyzing 1536 SNPs. 34 The selection of SNPs in both the present study and the study of de Krom et al. 34 was very similar. In our sample, we examined 12 SNPs in the DRD3 gene covering 98% of the most common HapMap phase II variants based on the CEU (Utah residents of Northern and Western European ancestry) panel, whereas de Krom et al. analyzed 11 SNPs in the same gene. The association of this genetic polymorphism with ASD and AP-induced EPS could indicate functional properties for this SNP, or more probably, as this SNP is located in intronic regions, LD with other functional SNPs. Moreover, ASD patients have greater liability to side effects of AP medication and movement disorders.
However, some issues need to be addressed. First, the sample size (n ¼ 270), though limited, was higher than the mean sample size used in pharmacogenetic studies of acute AP-induced EPS (n ¼ 150). [7] [8] [9] [10] 32, 33, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] In fact, to our knowledge, only one study of Caucasians had a larger sample (n ¼ 665). 36 Second, although Bonferroni correction seems the most appropriate way to correct for multiple testing, it may be overly conservative. Therefore, we may miss other loci that could be associated with AP-induced EPS. This is the case of the three SNPs of the DAT gene with P-valueso0.01. These SNPs present with lower LD values and are in different haplotype blocks, which seems to indicate an independent contribution to AP-induced EPS risk. However, we do not have enough statistical power to rule out the contribution of these SNPs and the other genes studied (different to DRD3), although their contribution to the overall risk of AP-induced EPS is probably small.
In conclusion, AP-induced EPS remains a serious public health problem, and our finding of a common SNP (rs167771) in the DRD3 gene provides a strong new candidate gene for AP-induced EPS. Further studies are needed to confirm this association, in which case it could be included in clinical practice as a possible risk factor for EPS.
Materials and methods

Subjects
Sample size calculations assuming a 5% level of significance, 80% power and a schizophrenia risk (odds ratio) of 2 .
Effects of DRD3 polymorphisms in risperidone-induced EPS P Gassó et al associated with carrying the studied alleles and allelic frequencies from 0.05 (n ¼ 210 cases) to 0.5 (n ¼ 140 cases). Calculations were performed with Quanto1.2 software (http://hydra.usc.edu/gxe). A cohort of 321 psychiatric inpatients receiving AP therapy was recruited consecutively in the Psychiatry Service of the Hospital Clínic (Barcelona, Spain) over a period of 3 years (2002) (2003) (2004) . Two hundred and seventy subjects of this cohort participated in the pharmacogenetic study of EPS presented here. One hundred and ninety-seven subjects were diagnosed with schizophrenia (n ¼ 133) and related disorders (n ¼ 21 schizoaffective disorder, n ¼ 29 acute psychotic disorder, n ¼ 10 delusional paranoid disorder, n ¼ 4 schizotypical disorder). Forty-two were diagnosed as having bipolar disorders using DSM-IV criteria, 46 and 31 had other diagnoses (including personality disorder, psychotic depression, behavior disorder, mild cognitive impairment and obsessive-compulsive disorder). Diagnoses of cases were established using the SCID-DSM-IV version. The reliability and validity of the SCID-IV has been reported in several published studies. 47 Information on age, gender, smoking and substance abuse was recorded. All those participating in the study were Caucasians, living in Catalonia. Catalonia is a region in northeast Spain with 7,210,508 habitants, 96.2% of which are Caucasians (http://www.idescat.cat/cat/idescat/ publicacions/anuari/). Ethnicity was determined by selfreported ancestries; cases and controls reported ancestries for each grandparent. We excluded subjects mentioning nonEuropean ancestry. Written informed consent was obtained from each subject. The study was approved by the Ethics Committee of the hospital.
Status of EPS
Acute EPS induced by AP medication was evaluated using the Simpson-Angus Scale. 48 Eighty-one patients presenting with EPS (Simpson-Angus 43) during the hospitalization period and/or a history of movement disorders were considered as cases. One hundred and eighty-nine patients presenting without EPS (Simpson-Angus p3) at the time of the study or earlier were taken as controls. The period of treatment was at least 15 days. Patients treated with AP drugs for fewer than 15 days and who did not present with EPS (controls) were ruled out. Patients receiving anticholinergic treatment, antidepressants or mood stabilizers at the beginning of the AP treatment were also excluded. The inpatients were observed for 48 h (without AP medication) after admission, in case of acute exacerbation or first psychotic episodes.
AP dosage
The daily AP dosage was calculated as the CEDD. 49 AmiSulpride (n ¼ 4) and long-acting injectable risperidone (LAIR) (n ¼ 2) conversion was not possible because there were no tables available. The total calculated CEDD included dosage addition when two APs were administered together (cases n ¼ 8, controls n ¼ 29). This total CEDD was categorized into three groups: low p200 mg, medium 201-399 mg and high X400 mg. In this new variable (CEDD), we included the AmiSulpride (low p25 mg, medium 25-50 mg, high X50 mg) and LAIR (low p400 mg, medium 401-599 mg, high X600 mg) dosage in each corresponding category.
We categorized each AP drug for its EPS potency in three categories: high, medium or low. [50] [51] [52] For zuclopentixol, data were collected from Duphar-Nezel Laboratories (Sovany) ( Table 1) .
Compliance was monitored in accord with established nursing protocols.
SNP selection, genotyping and quality control A total of 90 SNPs were selected in seven-candidate gene regions (covering target loci and upstream and downstream regions) by tagging analysis (as implemented in Haploview 4.1) at an r 2 threshold of 0.8 to capture 98% of the most common HapMap phase II variants based on the CEU panel (minor allele frequency40.05) (range 91-100% for individual genes). Six SNPs were rejected before genotyping because of assay rules. The remaining 84-tag SNPs Table 5 Genotyped SNPs in each candidate gene   ACE  COMT  DAT  DRD2  DRD3  MAO-A  MAO-B   rs4459609  rs737864  rs4975636  rs12422191  rs4646996  rs5906957  rs1799836  rs4316  rs4818  rs27072  rs2234689  rs3773679  rs3027392  rs3027448  rs4343  rs4646316  rs11564772  rs2734841  rs3773678  rs6323  rs3027450  rs4461142  rs9332377  rs6347  rs1124491  rs2630349  rs5905859  rs2311013  rs4267385  rs165849  rs27048  rs2440390  rs167771  rs3027401  rs6651806  rs2518823  rs37022  rs17115583  rs167770  rs12843533  rs12851487  rs887199  rs2975292  rs11214606  rs11706283  rs6609257  rs5905512  rs2239395  rs2735917  rs17529477  rs16822416  rs3027415  rs1181252  rs11564758  rs4245147  rs6280  rs1183035  rs10052016  rs7131056  rs324026  rs460700  rs11214613  rs1800828  rs420422  rs12364283  rs9813633  rs2550956 rs10891556 rs3756450
Effects of DRD3 polymorphisms in risperidone-induced EPS P Gassó et al were genotyped by the SNPlex genotyping system (Applied Biosystems, Foster City, CA, USA) at the Barcelona Node of the Spanish National Genotyping Centre (CeGen). We excluded 14 SNPs whose genotypes were called in o90% of the samples or had inconsistent clustering on inspection.
The 70-validated SNPs (Table 5 ) tagged 81% of the most common HapMap II variants (minor allele frequency40.05) (range 68-100% for individual genes).
For quality control, eight samples were genotyped in duplicate for all the SNPs analyzed, with a 100% concordance rate, and three SNPs were genotyped in all samples by alternative methods, such as restriction fragment length polymorphisms (rs6280 and rs6323) 12 or allele-specific oligonucleotide (rs2311013) analysis. 53 The concordance rates were 99.32, 99.88 and 99.45%, respectively.
Statistics
Data were analyzed using SPSS14.05 (statistical analysis software, SPSS Inc., Chicago, IL, USA). Means and standard deviations were computed for continuous variables. Univariate analysis (w 2 -test for categorical variables and t-student test for continuous variables) was used to identify variables associated with the risk of AP-induced EPS. To calculate the independent contribution to the risk of each of the 70-valid SNPs, tests were computed using the SNPassoc R package, 54 adjusting the analysis for those variables associated with the risk of AP-induced EPS (age, diagnoses, AP dosage and AP-DRD2 blockade potency). To check the Hardy-Weinberg equilibrium and to establish LD relationships between markers, we used Haploview 4.1. 55 We also carried out haplotypic analysis with SNPassoc. Exploratory analysis included the 'sliding windows' approach of two and three SNPs, starting with SNPs with nominal point wise (Po0.05) association. Corrections for multiple tests were made this way: the empirical significance of single SNP or genotype tests was defined using the Bonferroni correction (significant P-valueo 7.01 Â 10 À4 after Bonferroni correction); empirical P-values were determined for haplotype tests by 10,000 cycles of permutation when the nominal global P-value was o0.001.
